ESTRELLA IMMUNOPHARMA, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value
ESTRELLA IMMUNOPHARMA, INC. (ESLA) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value of $1.60 million for the 3-month period ending 2024-09-30, per its 10-Q filed 2024-11-14.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue · last filed 2024-11-14
- ESTRELLA IMMUNOPHARMA, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2024-09-30 was $1.60M.
- ESTRELLA IMMUNOPHARMA, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2024-06-30 was $0.00.
- ESTRELLA IMMUNOPHARMA, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2024-03-31 was $0.00.
- ESTRELLA IMMUNOPHARMA, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2024 was $1.60M.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 1 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 12 month |
|---|---|---|---|---|---|
| 2024-09-30 | $1.60M 10-Q · filed 2024-11-14 | $1.60M derived: sum of 2 quarters · filed 2024-11-14 | $1.60M derived: sum of 3 quarters · filed 2024-11-14 | ||
| 2024-06-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-09-27 | $0.00 derived: sum of 2 quarters · filed 2024-09-27 | $1.60M 10-K · filed 2024-09-27 | ||
| 2024-03-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-05-15 | $1.60M 10-Q · filed 2024-05-15 | |||
| 2023-12-31 | $1.60M 10-Q · filed 2024-02-14 | ||||
| 2023-09-29 | $1.60M 10-Q · filed 2023-11-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| Pluri Inc. (PLUR) | $0.014B | ||
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |